CJC-1295 · 2006
CJC-1295 randomized controlled study record
Journal of Clinical Endocrinology & Metabolism
Design
Two randomized, placebo-controlled, double-blind ascending-dose studies
Population
Healthy adults ages 21–61
Record scope
Short-duration biomarker and pharmacokinetic context involving GH and IGF-1 measures.
Limit: This record describes the published study context only. It does not establish individual benefit, safety, suitability, or a use recommendation.
